Zachary Fussell, APRN
Psychiatric/Mental Health · Shreveport, LANPI 1861114407
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,813 of the $9,191 with a category attached, or 74.1%. Otsuka America Pharmaceutical, Inc. accounts for 79.2% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $8,053, more than ten times the $76 reported in 2022. Among psychiatric/mental health clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 98 payments — averaging $93.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$7K
- AbbVie$756
- Braeburn Inc.$382
- Teva Pharmaceuticals USA, Inc.$187
- Neurocrine Biosciences, Inc.$180
- Indivior Inc.$147
- plus $256 from 7 others
What the payments were for
- Speaking & faculty fees$6,81374%
- Travel & lodging$1472%
- Food & beverage$2,23124%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 24 | $7,281 |
| AbbVie | 32 | $756 |
| Braeburn Inc. | 9 | $382 |
| Teva Pharmaceuticals USA, Inc. | 4 | $187 |
| Neurocrine Biosciences, Inc. | 10 | $180 |
| Indivior Inc. | 8 | $147 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $84 |
| Alkermes, Inc. | 2 | $46 |
| Alpha Cognition USA, Inc. | 1 | $32 |
| Johnson & Johnson | 1 | $28 |
| Lundbeck LLC | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,191 in reported general payments places this provider in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 183 | $131,196 |
| IngrezzaValbenazine Tosylate | 12 | $45,105 |
| NuedextaDextromethorphan Hbr/Quinidine | 55 | $40,928 |
| VraylarCariprazine Hcl | 20 | $14,392 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 57 | $11,096 |
| Olanzapine | 159 | $3,796 |
| Buprenorphine Hcl | 59 | $2,967 |
| Mirtazapine | 105 | $2,581 |
| Quetiapine Fumarate | 101 | $1,768 |
| Duloxetine Hcl | 48 | $1,385 |
| Sertraline Hcl | 117 | $1,185 |
| Valproic AcidValproic Acid (As Sodium Salt) | 27 | $1,086 |
| Divalproex Sodium | 53 | $914 |
| Trazodone Hcl | 62 | $836 |
| Aripiprazole | 19 | $545 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $7,281 | $131,196183 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $180 | $45,10512 claims |
| AbbVieVraylar | $756 | $14,39220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Shreveport
- Kimberly ForcinelShreveport$92K
- Lisa BakerShreveport$9K
- Jaschandria BellShreveport$8K
- Shannon JacksonShreveport$8K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Sattaria DilksLake Charles$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.